Antibacterial Resistance Leadership Group 2.0: Back to Business.
| dc.contributor.author | Chambers, Henry F | |
| dc.contributor.author | Evans, Scott R | |
| dc.contributor.author | Patel, Robin | |
| dc.contributor.author | Cross, Heather R | |
| dc.contributor.author | Harris, Anthony D | |
| dc.contributor.author | Doi, Yohei | |
| dc.contributor.author | Boucher, Helen W | |
| dc.contributor.author | van Duin, David | |
| dc.contributor.author | Tsalik, Ephraim L | |
| dc.contributor.author | Holland, Thomas L | |
| dc.contributor.author | Pettigrew, Melinda M | |
| dc.contributor.author | Tamma, Pranita D | |
| dc.contributor.author | Hodges, Kathryn R | |
| dc.contributor.author | Souli, Maria | |
| dc.contributor.author | Fowler, Vance G | |
| dc.date.accessioned | 2022-02-01T19:59:25Z | |
| dc.date.available | 2022-02-01T19:59:25Z | |
| dc.date.issued | 2021-08 | |
| dc.date.updated | 2022-02-01T19:59:24Z | |
| dc.description.abstract | In December 2019, the Antibacterial Resistance Leadership Group (ARLG) was awarded funding for another 7-year cycle to support a clinical research network on antibacterial resistance. ARLG 2.0 has 3 overarching research priorities: infections caused by antibiotic-resistant (AR) gram-negative bacteria, infections caused by AR gram-positive bacteria, and diagnostic tests to optimize use of antibiotics. To support the next generation of AR researchers, the ARLG offers 3 mentoring opportunities: the ARLG Fellowship, Early Stage Investigator seed grants, and the Trialists in Training Program. The purpose of this article is to update the scientific community on the progress made in the original funding period and to encourage submission of clinical research that addresses 1 or more of the research priority areas of ARLG 2.0. | |
| dc.identifier | 6137279 | |
| dc.identifier.issn | 1058-4838 | |
| dc.identifier.issn | 1537-6591 | |
| dc.identifier.uri | ||
| dc.language | eng | |
| dc.publisher | Oxford University Press (OUP) | |
| dc.relation.ispartof | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | |
| dc.relation.isversionof | 10.1093/cid/ciab141 | |
| dc.subject | Gram-Negative Bacteria | |
| dc.subject | Gram-Positive Bacteria | |
| dc.subject | Anti-Bacterial Agents | |
| dc.subject | Leadership | |
| dc.subject | Drug Resistance, Bacterial | |
| dc.title | Antibacterial Resistance Leadership Group 2.0: Back to Business. | |
| dc.type | Journal article | |
| duke.contributor.orcid | Tsalik, Ephraim L|0000-0002-6417-2042 | |
| duke.contributor.orcid | Holland, Thomas L|0000-0001-7745-9010 | |
| duke.contributor.orcid | Fowler, Vance G|0000-0002-8048-0897 | |
| pubs.begin-page | 730 | |
| pubs.end-page | 739 | |
| pubs.issue | 4 | |
| pubs.organisational-group | Duke | |
| pubs.organisational-group | School of Medicine | |
| pubs.organisational-group | Basic Science Departments | |
| pubs.organisational-group | Clinical Science Departments | |
| pubs.organisational-group | Institutes and Centers | |
| pubs.organisational-group | Molecular Genetics and Microbiology | |
| pubs.organisational-group | Medicine | |
| pubs.organisational-group | Medicine, Infectious Diseases | |
| pubs.organisational-group | Duke Clinical Research Institute | |
| pubs.publication-status | Published | |
| pubs.volume | 73 |
Files
Original bundle
- Name:
- Chambers ARLG 2.0 CID 2021.pdf
- Size:
- 311.06 KB
- Format:
- Adobe Portable Document Format